CA1261269A - Herpes simplex treatment - Google Patents
Herpes simplex treatmentInfo
- Publication number
- CA1261269A CA1261269A CA000473085A CA473085A CA1261269A CA 1261269 A CA1261269 A CA 1261269A CA 000473085 A CA000473085 A CA 000473085A CA 473085 A CA473085 A CA 473085A CA 1261269 A CA1261269 A CA 1261269A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- vitamin
- bis
- diacetate
- phenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
There is disclosed a method for treating Herpes Simplex infection condition which includes administering to a person having said condition an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester). Also disclosed are appropriate dosage compositions, normally containing 0.1-3.5 mg of active ingredient in association with a pharmaceutically acceptable carrier.
There is disclosed a method for treating Herpes Simplex infection condition which includes administering to a person having said condition an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester). Also disclosed are appropriate dosage compositions, normally containing 0.1-3.5 mg of active ingredient in association with a pharmaceutically acceptable carrier.
Description
M247:15990:WP~
HERPES SIMPLEX TREATMENT
Technical Field This invention relates to treatment of Herpes Simplex (Herpesvirus Hominis), a viral disease of widespread occurrence. Herpes Simplex occurs in two antigenic tyes, Herpes febrilis and Herpes genitalis, referred as Type 1 and Type 2. Infection is usually manifested by the appearance of vesicular eruptions, oral herpetic lesions, commonly referred to as fever blisters, or cold sores about the lips in the instance of Herpes Simplex Type l, and vesicular lesions on and about the male or female genitalia in the instance of Herpes Simplex Type 2. Persons with Herpes Simplex infections are likely to have recurrent periods of - lesion development spaced by periods of remission.
HERPES SIMPLEX TREATMENT
Technical Field This invention relates to treatment of Herpes Simplex (Herpesvirus Hominis), a viral disease of widespread occurrence. Herpes Simplex occurs in two antigenic tyes, Herpes febrilis and Herpes genitalis, referred as Type 1 and Type 2. Infection is usually manifested by the appearance of vesicular eruptions, oral herpetic lesions, commonly referred to as fever blisters, or cold sores about the lips in the instance of Herpes Simplex Type l, and vesicular lesions on and about the male or female genitalia in the instance of Herpes Simplex Type 2. Persons with Herpes Simplex infections are likely to have recurrent periods of - lesion development spaced by periods of remission.
2~ Management of the condition involves easing the itching sensation which accompanies the lesion periods, and speeding remission.
Background Art While no cure is presently known for Herpes Simplex in either form, certain substances have been advanced for management of the disease. In U.S~P. 4,256,763 to McHugh a method of treating inflammatory viral infections such as Herpes Simplex and acne was ; 35 ' ~
. . _s I
~ 3 1 dIsclosed involving the application of 3,3-bis (p-hydroxyphenyl) phthalide, in amounts up to lO0 milligrams, preferably 15 to 30 milligrams initially and repetitively at predetermined intervals.
Because 3,3-bis (p-hydroxyphenyl) phthalide is a cathartic, there is an unpleasant side effect ~o its use which suggests reduced usage concentratiorls, but the patentee does not suggest any lower dosage will be efEective in Herpes Simplex management.
Summary of the Invention -It is an object of the present invention to provide an effective Herpes Simplex treatment at much reduced dosage levels to minimize side effects. It is another object to provide a new ~se for phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).
It is a further object to provide for the rapid amelioration of Herpes Simplex symptoms, itching, lesion development and the like, by treatment with quite low quantities of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), and to maintain the patient in a remissive state with continued low dosage treatment after remission. Still other objects include provision of products comprising phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), carriers and therapeutic agents for coapplication with phenol, ~,4'-(2-pyridinyl methylene) bis diacetate (ester).
- These and other objects of the invention to become ``
apparent hereinafter, are realized in accordance with the invention in the method of treatment of Herpes Simplex infection condition which includes administering an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) to a person having an , . ~ ..
' ''~
-~
~ 3 1 Herpes Simplex condtion.
In particular embodiments, the method includes administering such dosage orally, administering a dosage of from about 0.1 to about 9.5 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), suspending the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in a carrier for administration, combining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) with a second therapeutic agent in an effective dosage for administration therewith, e.g. by selecting an effective dosage of one or more vitamins for coadministration with the phenol, 4,4'-t2-PYridinYl methylene) bis diacetate (ester), and carrier if any, and maintaining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) free of enteric coating for administration.
The invention further contemplates provision of a product comprising a dosage of phenol, 4,4'-~2-pyridinyl methylene) bis, diacetate (ester) effective upon oral ingestion- for management of Herpes Simplex, and less than is effective for catharsis of the person receiving the dosage and combined with an ingestible carrier. Typically, the product comprises a dosage between 0.1 and 9.5 milligrams, and may further comprise one or more vitamins in effective dosage, preferably free of an enteric coating.
..
''~
15990 -~-l Preferred Modes _ _ .
Phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester~, commonly referred to as Bisacodyl, is a diphenyl trimethane suitably prepared from 2-pyridine-carboxaldehyde condensed with phenol in the presenceof sulfuric acid or other dehydrant, followed by esterification with acetic anhydride and anhydrous sodium acetate, as described in U.S.P. 2l764,590. It is a white to off-white crystalline powder slightly soluble in water but fairly soluble in common organic solvents. It is known to be used as a contact laxative, acting to increase peristalsis throughout the large intestlne. A typical dose as a laxative is oral or rectal not less than 10 milligrams and up to 30 milligrams and is administered in an enteric coating to ensure passage to the larage intestine. It is known to inhibit glucose absorption and intestinal Na-K-ATPase activity.
The effectiveness of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in treatment of Herpes Simplex is not to be expected from a study of its past usages or chemical structure, and is not scientifically explainable at this time. It has been found surprisingly effective in Herpes Simplex management, causing nearly immediate remission and suppressing recurrence, although administered at quite moderate levels, less than those recommended for laxative action, and far less than 3,3-bis (p-hydroyphenyl) phthalide dosages recommended in U.S.P.
4,256,7~3. The use of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) as taught herein thus enables Herpes Simplex management with reduced .
~'' '''~
~. ~
' ` ~
.
; '. ~, ' 15990 _5_ 1 incidence of side effects than encountered with the use of alternate methodologies.
The phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (s~ter) may be combined with other therap~utic agents each for its own purpose e.g. to reli~ve stress, or to enhance the ef~ectivenes~ of the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester~ when administered. Such agents as vitamins A, D, E, C, Folic acid, 3-1, B-2, Niacin, B-6, and B-12, among others can be comblned with the phenol, 4,4'-~2-pyridinyl methylene) bis diacetate (ester). Other agents for combining with phenol, 4,4'-(2-pyridinyl methylcnc) bi~
diacetate (ester) include amino acids, such as lysine and leucine; proteins such as gelatin and gliadin; or carbohydrates, e.g. starch, lactose and the likc.
Whether administered orally, topically or intra-venously, ~he phenol, 4,4'-(2-pyridinyl me~hylene) bis,- diacetate ~ester) may be suitably dispersed in a carrier, e.g. tablet or capsule carriers and components such as cxcipients, bulking agents, lubricants, disintegrants, dyes and the like as are known in tablet ma~ing technology for the purposc of easing the administration of the phenol, 4,4'-(2-pyridinyl methylene) bis diacetate ~ester). The term carrier further embraces vehicles used or useful in preparing injection form o the phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) prioducts of the invention, such as sesame oil and the like.
It is convenient to provide capsules or tablets of the composition according to the invention in sets or groups, of a sufficient number and strength to constitute a daily dosage of an appropriate amount. A typical total daily dose is ~rom about 10 to about 13 mg, and it is conveniently provided in 3-4 mg units ~capsules or tablets), ~5 one uni~ to be taken orally at intervals of 6-12 hours to -5a-provide the appropriate total daily dose.
EXAMPLE I
Capsules of phe'n,ol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) were prepared by mixing per :
:
: ~ : : : :
:
.
t;'3 l5990 ; -6-1 capsule 3.35 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate ~ester) with 490 milligrams of an aliquot of a mixture oE vitamins comprising:
Vitamin A2500 units Vitamin D400 units Vitamin E15 units Vitamin C 60 mg.
Folic acid 0.3 mg.
Vitamin B-l 1.0 mg.
Vitamin B-2 1.2 mg.
Niacin 13.5 mg.
Vitamin B-6 1.0 mg.
Vitamin B-12 4.5 mg.
blended with 2 parts of cornstarch per part of vitamin mix.
Adult males having a virulent recurrence of Herpes Simplex Types 1 and 2 were given a series of EXAMPLE
I capsules prepared as above, or a like CONTROL I
capsule prepared with phenolphthalein 3,3-bis (p-hydroxyphenyl phthalide) rather than phenol, 4,4'-(2-pyridinyl methylene) bis diacetate [ester), or a CONTROL II as taught in U.S~P. 4,256,763. The CONTROL II capsules comprised:
Phenolphthalein 30 mg.
Acetominophen325 mg.
Chlorpheniramine Maleate2 mg. ``
; Caffein 33 mg.
Phenylephrine HCL 10 mg.
The effective dosage rate for the CONTROL I and II
treatments was 30 milligrams per 8 hours for the first day, and a like amount at 12 hour intervals .
., .
15990 ~7~
thereafter. The EXAMPLE I dosage rate was one capsule (3.35 mg. per dosage) every six to eight hours on the first day and thereafter at 8 to 12 hour intervals.
All subjects showed rapid remission. The EXAMPLE
I material was no less effective for being at the reduced dosage rate, and incidence of diarrhea from the laxative effect was less of a problem than with the CONTROL I and II tests.
The inclusion of vitamins in the EXA.~PLE I
formulation adds stress relief factors to the formulation to ameliorate the stress which often accompanies onset of a Herpes condition.
EXA.~PLE II
A second capsule formula of the invention composition ~as prepared from:
phenol, 4~4'-(2-pyridinyl methylene) bis diacetate ~ester)3.5 mg.
phenacetin 350. mg.
chloropheniramine maleate3. mg.
caffein 38. mg.
phenylpropanolamine HCL9. mg.
by blending the ingredients eutectically.
EXAMPLE III
A tablet form of the invention dosage is prepared by blending phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 100 mg. lactose, 100 mgO
starch, and 10 mg. taic as a lubricant. It will be noted that this formulation can be packaged in bapsule form with the omission of the talc and adjusting ~he lactose and starch concentration`accordingly.
.
. ' ' ;~. . .
...........
i9 EXAMPLE IV
A protein containing capsule is prepared by blending eutectlcally phenol, 4,4'--(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 200 mg. lactose, 100 mg.
gliadin or gelatin protein, and about 100 mg. of the amino acid lysine.
EXAMPLE V
An intramuscular injectable formulation is prepared by blending, per dosage, 5 cc. sesame oil, 250 units of Vitamin E, and 5 mg. of phenol, 4,4'-(2-pyridinyl methylene) bls diacetate (ester).
'`''` '' ... . . ...
Background Art While no cure is presently known for Herpes Simplex in either form, certain substances have been advanced for management of the disease. In U.S~P. 4,256,763 to McHugh a method of treating inflammatory viral infections such as Herpes Simplex and acne was ; 35 ' ~
. . _s I
~ 3 1 dIsclosed involving the application of 3,3-bis (p-hydroxyphenyl) phthalide, in amounts up to lO0 milligrams, preferably 15 to 30 milligrams initially and repetitively at predetermined intervals.
Because 3,3-bis (p-hydroxyphenyl) phthalide is a cathartic, there is an unpleasant side effect ~o its use which suggests reduced usage concentratiorls, but the patentee does not suggest any lower dosage will be efEective in Herpes Simplex management.
Summary of the Invention -It is an object of the present invention to provide an effective Herpes Simplex treatment at much reduced dosage levels to minimize side effects. It is another object to provide a new ~se for phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester).
It is a further object to provide for the rapid amelioration of Herpes Simplex symptoms, itching, lesion development and the like, by treatment with quite low quantities of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), and to maintain the patient in a remissive state with continued low dosage treatment after remission. Still other objects include provision of products comprising phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), carriers and therapeutic agents for coapplication with phenol, ~,4'-(2-pyridinyl methylene) bis diacetate (ester).
- These and other objects of the invention to become ``
apparent hereinafter, are realized in accordance with the invention in the method of treatment of Herpes Simplex infection condition which includes administering an effective dosage of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) to a person having an , . ~ ..
' ''~
-~
~ 3 1 Herpes Simplex condtion.
In particular embodiments, the method includes administering such dosage orally, administering a dosage of from about 0.1 to about 9.5 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), suspending the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in a carrier for administration, combining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) with a second therapeutic agent in an effective dosage for administration therewith, e.g. by selecting an effective dosage of one or more vitamins for coadministration with the phenol, 4,4'-t2-PYridinYl methylene) bis diacetate (ester), and carrier if any, and maintaining the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) free of enteric coating for administration.
The invention further contemplates provision of a product comprising a dosage of phenol, 4,4'-~2-pyridinyl methylene) bis, diacetate (ester) effective upon oral ingestion- for management of Herpes Simplex, and less than is effective for catharsis of the person receiving the dosage and combined with an ingestible carrier. Typically, the product comprises a dosage between 0.1 and 9.5 milligrams, and may further comprise one or more vitamins in effective dosage, preferably free of an enteric coating.
..
''~
15990 -~-l Preferred Modes _ _ .
Phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester~, commonly referred to as Bisacodyl, is a diphenyl trimethane suitably prepared from 2-pyridine-carboxaldehyde condensed with phenol in the presenceof sulfuric acid or other dehydrant, followed by esterification with acetic anhydride and anhydrous sodium acetate, as described in U.S.P. 2l764,590. It is a white to off-white crystalline powder slightly soluble in water but fairly soluble in common organic solvents. It is known to be used as a contact laxative, acting to increase peristalsis throughout the large intestlne. A typical dose as a laxative is oral or rectal not less than 10 milligrams and up to 30 milligrams and is administered in an enteric coating to ensure passage to the larage intestine. It is known to inhibit glucose absorption and intestinal Na-K-ATPase activity.
The effectiveness of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) in treatment of Herpes Simplex is not to be expected from a study of its past usages or chemical structure, and is not scientifically explainable at this time. It has been found surprisingly effective in Herpes Simplex management, causing nearly immediate remission and suppressing recurrence, although administered at quite moderate levels, less than those recommended for laxative action, and far less than 3,3-bis (p-hydroyphenyl) phthalide dosages recommended in U.S.P.
4,256,7~3. The use of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester) as taught herein thus enables Herpes Simplex management with reduced .
~'' '''~
~. ~
' ` ~
.
; '. ~, ' 15990 _5_ 1 incidence of side effects than encountered with the use of alternate methodologies.
The phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (s~ter) may be combined with other therap~utic agents each for its own purpose e.g. to reli~ve stress, or to enhance the ef~ectivenes~ of the phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate (ester~ when administered. Such agents as vitamins A, D, E, C, Folic acid, 3-1, B-2, Niacin, B-6, and B-12, among others can be comblned with the phenol, 4,4'-~2-pyridinyl methylene) bis diacetate (ester). Other agents for combining with phenol, 4,4'-(2-pyridinyl methylcnc) bi~
diacetate (ester) include amino acids, such as lysine and leucine; proteins such as gelatin and gliadin; or carbohydrates, e.g. starch, lactose and the likc.
Whether administered orally, topically or intra-venously, ~he phenol, 4,4'-(2-pyridinyl me~hylene) bis,- diacetate ~ester) may be suitably dispersed in a carrier, e.g. tablet or capsule carriers and components such as cxcipients, bulking agents, lubricants, disintegrants, dyes and the like as are known in tablet ma~ing technology for the purposc of easing the administration of the phenol, 4,4'-(2-pyridinyl methylene) bis diacetate ~ester). The term carrier further embraces vehicles used or useful in preparing injection form o the phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) prioducts of the invention, such as sesame oil and the like.
It is convenient to provide capsules or tablets of the composition according to the invention in sets or groups, of a sufficient number and strength to constitute a daily dosage of an appropriate amount. A typical total daily dose is ~rom about 10 to about 13 mg, and it is conveniently provided in 3-4 mg units ~capsules or tablets), ~5 one uni~ to be taken orally at intervals of 6-12 hours to -5a-provide the appropriate total daily dose.
EXAMPLE I
Capsules of phe'n,ol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) were prepared by mixing per :
:
: ~ : : : :
:
.
t;'3 l5990 ; -6-1 capsule 3.35 milligrams of phenol, 4,4'-(2-pyridinyl methylene) bis,- diacetate ~ester) with 490 milligrams of an aliquot of a mixture oE vitamins comprising:
Vitamin A2500 units Vitamin D400 units Vitamin E15 units Vitamin C 60 mg.
Folic acid 0.3 mg.
Vitamin B-l 1.0 mg.
Vitamin B-2 1.2 mg.
Niacin 13.5 mg.
Vitamin B-6 1.0 mg.
Vitamin B-12 4.5 mg.
blended with 2 parts of cornstarch per part of vitamin mix.
Adult males having a virulent recurrence of Herpes Simplex Types 1 and 2 were given a series of EXAMPLE
I capsules prepared as above, or a like CONTROL I
capsule prepared with phenolphthalein 3,3-bis (p-hydroxyphenyl phthalide) rather than phenol, 4,4'-(2-pyridinyl methylene) bis diacetate [ester), or a CONTROL II as taught in U.S~P. 4,256,763. The CONTROL II capsules comprised:
Phenolphthalein 30 mg.
Acetominophen325 mg.
Chlorpheniramine Maleate2 mg. ``
; Caffein 33 mg.
Phenylephrine HCL 10 mg.
The effective dosage rate for the CONTROL I and II
treatments was 30 milligrams per 8 hours for the first day, and a like amount at 12 hour intervals .
., .
15990 ~7~
thereafter. The EXAMPLE I dosage rate was one capsule (3.35 mg. per dosage) every six to eight hours on the first day and thereafter at 8 to 12 hour intervals.
All subjects showed rapid remission. The EXAMPLE
I material was no less effective for being at the reduced dosage rate, and incidence of diarrhea from the laxative effect was less of a problem than with the CONTROL I and II tests.
The inclusion of vitamins in the EXA.~PLE I
formulation adds stress relief factors to the formulation to ameliorate the stress which often accompanies onset of a Herpes condition.
EXA.~PLE II
A second capsule formula of the invention composition ~as prepared from:
phenol, 4~4'-(2-pyridinyl methylene) bis diacetate ~ester)3.5 mg.
phenacetin 350. mg.
chloropheniramine maleate3. mg.
caffein 38. mg.
phenylpropanolamine HCL9. mg.
by blending the ingredients eutectically.
EXAMPLE III
A tablet form of the invention dosage is prepared by blending phenol, 4,4'-(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 100 mg. lactose, 100 mgO
starch, and 10 mg. taic as a lubricant. It will be noted that this formulation can be packaged in bapsule form with the omission of the talc and adjusting ~he lactose and starch concentration`accordingly.
.
. ' ' ;~. . .
...........
i9 EXAMPLE IV
A protein containing capsule is prepared by blending eutectlcally phenol, 4,4'--(2-pyridinyl methylene) bis diacetate (ester), 3.5 mg., 200 mg. lactose, 100 mg.
gliadin or gelatin protein, and about 100 mg. of the amino acid lysine.
EXAMPLE V
An intramuscular injectable formulation is prepared by blending, per dosage, 5 cc. sesame oil, 250 units of Vitamin E, and 5 mg. of phenol, 4,4'-(2-pyridinyl methylene) bls diacetate (ester).
'`''` '' ... . . ...
3 0 - ~. - : :. ~ : . .. .. ~ . .- . - .
.. ... .
' ? { ~ ~ . . .` ` C ~
.
: . .
.,: . . ~ :: .
..
:. . :: :
.. ... .
' ? { ~ ~ . . .` ` C ~
.
: . .
.,: . . ~ :: .
..
:. . :: :
Claims (14)
1. A composition for administratlon to mammals to treat Herpes Simplex infections therein, said composition comprising an effective dosage amount as active ingredient of phenol, 4,4'-(2-pyridinyl methylene) bis, diacetate (ester) in association with a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein said dosage amount of active ingredient therein is from about 0.1 mg to about 9.5 mg.
3. The composition of claim 1, and free of enteric coating.
4. The composition of claim 2, in capsule or tablet form adapted for oral administration to a patient.
5. The composition of claim 1, claim 2 or claim 3, wherein said dosage amount of active ingredient therein is from about 0.1 mg to about 3.5 mg.
6. The composition of claim 1, claim 2 or claim 3, also including at least one other therapeutic agent selected from vitamins, amino acids, proteins and carbohydrates.
7. The composition of claim 1, claim 2 and claim 3, also including at least one other therapeutic agent selected from vitamin A, vitamin D, vitamin E, vitamin C, folic acid, vitamin B-l, vitamin B-2, niacin, vitamin B-6 and vitamin B-12, and mixtures of two or more said agents.
8. The composition of claim 1, claim 2 or claim 3, also including an amino acid selected from lysine and leucine.
9. The composition of claim 1, claim 2 or claim 3, also including a protein selected from gelatin and gliadin.
10. The composition of claim 1, claim 2 or claim 3, also including a carbohydrate selected from starch, lactose, mono-saccharide sugars and disaccharide sugars.
11. An effective daily dosage of a composition according to claim 3, for administration to a human patient for treatment of Herpes Simplex viral infections therein, and comprising a plurality of individual orally administrable capsules or tablets, each containing from about 3 mg to about 4 mg of phenol, 4,4'-(2-pyridinyl methylene) bis,-diacetate (ester) as active ingredient, the total number of said capsules or tablets being sufficient to provide a total dosage of from about 10 mg to about 13 mg of active ingredient for administration to the patient over a period of 24 hours.
12. The composition of claim 1 or claim 2, in liquid suspension or solution for administration to a patient by injection.
13. The composition of claim 2, and free of enteric coating.
14. The composition of claim 4, and free of enteric coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000473085A CA1261269A (en) | 1985-01-29 | 1985-01-29 | Herpes simplex treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000473085A CA1261269A (en) | 1985-01-29 | 1985-01-29 | Herpes simplex treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1261269A true CA1261269A (en) | 1989-09-26 |
Family
ID=4129706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000473085A Expired CA1261269A (en) | 1985-01-29 | 1985-01-29 | Herpes simplex treatment |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1261269A (en) |
-
1985
- 1985-01-29 CA CA000473085A patent/CA1261269A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4588744A (en) | Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide | |
| US4256763A (en) | Treatment of herpes simplex infections and acne | |
| US6770635B1 (en) | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | |
| Morrison et al. | Vitamin absorption studies: I. Factors influencing the excretion of oral test doses of thiamine and riboflavin by human subjects | |
| US4314989A (en) | Methionine sulfoxide amflioration of acetaminophen toxicity | |
| US6558656B2 (en) | Oral and topical compositions and methods related thereto in the treatment of acne | |
| US4654323A (en) | Method and composition for the therapeutic and prophylactic treatment of trauma to the skin | |
| US4034114A (en) | Treatment of skin keratoses with retinal | |
| US4576951A (en) | Proglumide, pharmaceutical preparations and compositions including it for use in human pain relief | |
| US3560612A (en) | Method of alleviating hypercitricemia | |
| US4810707A (en) | Herpes simplex treatment | |
| CA1261269A (en) | Herpes simplex treatment | |
| US5151425A (en) | Method of and composition for treating inflammation and the immunological response thereto | |
| US3019165A (en) | Sunburn preventive and burn remedy | |
| US4520132A (en) | Use of undecylenic acid to treat herpes labialis | |
| US4438129A (en) | Use of clotrimazole to treat herpes labialis | |
| US4343799A (en) | Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity | |
| NO974486L (en) | Low-dose "Ridogrel" formulations and their use in the treatment of intestinal inflammation | |
| WO1986000016A1 (en) | Herpes simplex treatment | |
| EG17992A (en) | Preparation of a medicament for arthritis and theumatism | |
| US4302452A (en) | Use of derivatives of 6α-methylprednisolone as an antiemetic | |
| CA1207238A (en) | Use of haloprogin in the treatment of herpes labialis | |
| USRE32990E (en) | Use of undercylenic acid to treat herpes labialis | |
| US4438134A (en) | Use of tolnaftate to treat herpes labialis | |
| US4105794A (en) | Process of mitigating cholelithiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |